Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
41.95
-0.05 (-0.12%)
Apr 29, 2026, 1:30 PM CST
-28.04%
Market Cap 3.70B
Revenue (ttm) 7.67M
Net Income (ttm) -258.40M
Shares Out 87.98M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 127,616
Average Volume 346,487
Open 42.00
Previous Close 42.00
Day's Range 41.70 - 42.20
52-Week Range 39.75 - 76.50
Beta 0.53
RSI 43.29
Earnings Date May 8, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 35
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6657
Full Company Profile

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.

Financial Statements

News

There is no news available yet.